Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 3rd Dose Vaccine in Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years of age and older~* Patients who had received a solid organ (kidney, liver, lung, heart, and pancreas) transplant patient from living or deceased donors.~* Patients with active graft with at least one immunosuppressive medication~* Completed two doses of BNT162b2 vaccination at least 28 days ago~Exclusion Criteria:~* Patient with non-active graft~* Any significant side effect with previous COVID-19 vaccination~* Within 28 days of BNT162b2 vaccine completion~* Already received more than and equal to three doses of COVID-19 vaccination~* Previously received COVID-19 vaccine other than BNT162b2 vaccine~* Previously received monoclonal Antibody treatment that are specifically directed against the spike protein for Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV)-2 such as Mab, Bamlanivimab, etesevimab, Casirivimab, imdevimab, Sotrovimab and/or any combination.~* Thrombocytopenia (if less than 50,000 per microliter 30 days prior vaccination)~* History of Capillary Leak Syndrome~* Adults unable to consent~* Individuals who are not yet adults (younger than 18 year old)~* Vulnerable patients (prisoners)~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BNT162b2 vaccine Group (Type: EXPERIMENTAL): Participants in this arm will receive one booster dose of the BNT162b2.
- JNJ-78436735 vaccine Group (Type: EXPERIMENTAL): Participants in this arm will receive one booster dose of the JNJ-78436735

Based on this trial design, predict the completion outcome and termination type (if applicable).